# Spruce Biosciences, Inc. (SPRB)

> Source: Nexqual · https://nexqual.com/SPRB · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Spruce Biosciences, Inc. (SPRB), nexqual.com/SPRB" · informational, not investment advice.

**Price:** USD 41.47 (+6.39% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 38.98 · day 39.11–41.88 · 52w 38.06–163 · market cap $119M · NCM

## Key facts
- Analysts: Buy (mean 1.89 on a 1–5 scale) (9 analysts), mean target USD 148 (range 104–230).
- Total return with dividends: 1Y -73.5% vs S&P 500 +18.1%; 5Y -99.8% vs S&P 500 +85.1%.

## Analysts
Consensus Buy (mean 1.89 on a 1–5 scale), 9 analysts; mean target USD 148 (low 104, high 230).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-24 | Citizens | Reiterated | Market Outperform | $144 |
| 2026-09-17 | Lake Street | Initiated | Buy | $149 |
| 2026-08-17 | Guggenheim | Target lowered | Buy | $123 → $104 |
| 2026-08-13 | Citizens | Target lowered | Market Outperform | $150 → $144 |
| 2026-07-13 | B. Riley Securities | Initiated | Buy | $160 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -73.5% | -99.8% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -73.6% | -72.2% |
| Volatility (annualized) | 88.7% | 262.0% |
| Max drawdown | -75.3% (Oct 2025→Oct 2026) | -100.0% (Feb 2024→Aug 2025) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/SPRB · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt